W. L. Pol

发表

Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis

M. Roberts, B. Engelen, F. Muntoni, 2013, Neuromuscular Disorders.

RYR1‐related myopathies: a wide spectrum of phenotypes throughout life

B. Engelen, H. Scheffer, B. Küsters, 2015, European journal of neurology.

190th ENMC international workshop: Spinal muscular atrophy with respiratory distress/distal spinal muscular atrophy type 1 11–13 May 2012, Naarden, The Netherlands

K. von Au, B. Talim, W. L. van der Pol, 2013, Neuromuscular Disorders.

VCP mutations in familial and sporadic amyotrophic lateral sclerosis

Ewout J. N. Groen, P. V. van Vught, J. Veldink, 2012, Neurobiology of Aging.

Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

E. Mercuri, F. Muntoni, F. Rivier, 2017, The Lancet Neurology.

Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial

A. V. van Norden, M. Dijkgraaf, B. Kleine, 2010, The Lancet Neurology.

Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial

A. Algra, I. Tweel, E. Uijtendaal, 2010, Neuromuscular Disorders.

Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature

H. Franssen, B. Jacobs, N. Notermans, 2014, Journal of Neurology.